*Disseminated on Behalf of Medicus Pharma Ltd.
Krypton Street Announces (NASDAQ: MDCX) Is Back On Our Radar
This Morning—Friday, October 31, 2025
Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email. Here's Why We'll Be Watching (MDCX) So Closely Today...
An Analyst Target As High As $27 For (MDCX), Suggests Over 1,000%
Upside Potential From This Week's Range.
(MDCX) Has Moved Approximately 70% In Three Weeks And It's Now
Trending Near Or Above Its 5, 20, And 50-Day Moving Averages. With Less Than 5M Shares Listed As Available, (MDCX)'s Small Float Could Have The Potential For Big Moves If Demand Starts To Shift. Take A Look At (MDCX) Before The Bell Rings…
October 31, 2025
Last Look Before the Bell | See Why (MDCX) is Topping Our Watchlist Today Dear Reader, There's less than 10 minutes to go—have you pulled up (MDCX) yet? Before the spotlight finds a breakout story, there's a moment when the signs begin to align — quietly at first, then unmistakably. That's exactly where Medicus Pharma Ltd. (NASDAQ: MDCX) stands right now. We've covered this profile before, but with fresh catalysts stacking up, it's back on our radar heading into Friday morning, October 31, 2025. Keep in mind, (MDCX) has an ultra-small float, with fewer than 5M shares listed as available to the public according to MarketWatch. When floats are this small, there's often potential for sharp moves if demand begins to shift. The chart now shows (MDCX) trending near or above its 5, 20, 50, and 100-day moving averages, showcasing potential technical strength. Last month, (MDCX) made an approximate 70% move in just three weeks—from $1.79 on September 4 to $3.05 on September 23—and could now be drawing sharper attention to what might come next. Insider ownership remains above 50%, a level that often reflects management confidence in a company's long-term direction. Together, these signals point toward potential for continued momentum. Analyst Targets Suggest Strong Upside Potential
Multiple market outlets, including Benzinga, MarketWatch, and TipRanks, have reported that D. Boral Capital analyst Jason Kolbert recently set a $27 target on (MDCX), suggesting over 1,000% upside potential from this week's $2.40 range. That's not the only target now in play. Brookline Capital's Kumaraguru Raja recently raised his target from $12 to $20, while Maxim Group's Jason McCarthy reiterated a $20 target in a report published a few days ago—reflecting continued confidence and over 700% upside potential from current levels. Following its recent acquisition of Antev Limited, (MDCX) has expanded into two late-stage therapeutic programs addressing major clinical needs. With analyst coverage, regulatory progress, and technical momentum all converging, (MDCX) stands out as one of the biotech names to watch heading into this morning's session. FDA Feedback Strengthens (MDCX)'s Path Toward Next-Gen
Skin Cancer Treatment
Medicus Pharma Ltd. (NASDAQ: MDCX) has announced positive feedback from a Type C meeting with the U.S. FDA regarding its SkinJect program — a dissolvable microneedle patch designed to non-invasively treat basal cell carcinoma (BCC). The FDA agreed that the company may pursue the 505(b)(2) regulatory pathway, a streamlined route that could reduce both cost and development time by leveraging existing doxorubicin safety data. The agency also provided constructive guidance on study design, endpoints, and formulation refinements, including recommendations for an adhesive layer and applicator system to improve precision and consistency. (MDCX) is currently advancing two Phase 2 studies for its SkinJect program. In the United States, the SKNJCT-003 trial has already enrolled more than 75% of its planned 90 participants and continues to show encouraging progress following a positively trending interim analysis earlier this year. At the same time, a second Phase 2 study (SKNJCT-004) is underway across six clinical sites in the United Arab Emirates, including Cleveland Clinic Abu Dhabi and Sheikh Shakbout Medical City. The company expects to complete patient recruitment for SKNJCT-003 before the end of Q4 2025 and to request an End-of-Phase 2 meeting with the FDA in Q1 2026. Medicus estimates that the market potential for non-invasive BCC treatments could approach $2B annually. Executive Chairman and CEO Dr. Raza Bokhari stated that the FDA's feedback "marks an important step toward establishing SkinJect as a potential first-in-market, non-invasive therapy for BCC," adding that confidence continues to grow as development progresses. (MDCX) Expands Compassionate Use Access With New Collaboration
Medicus Pharma Ltd. (NASDAQ: MDCX) announced a collaboration with the Gorlin Syndrome Alliance (GSA) to pursue a compassionate use pathway for its investigational SkinJect™ microneedle patch in patients with Gorlin Syndrome, a rare genetic condition affecting roughly 1 in 31,000 people worldwide. The partnership will jointly advance an Expanded Access IND Program with the FDA, allowing eligible patients with multiple or inoperable basal cell carcinomas to access SkinJect™ under physician supervision. The initiative also aims to collect real-world safety data while incorporating patient insights into ongoing development. Executive Chairman and CEO Dr. Raza Bokhari noted that the collaboration reflects (MDCX)'s mission to bring targeted innovation to conditions with significant unmet medical needs. First Patient Treated in UAE Marks Key Milestone in
Global Phase 2 Expansion
Just this week, Medicus Pharma Ltd. (NASDAQ: MDCX) announced that its first patient has been treated in the UAE SKNJCT-004 Phase 2 study for its SkinJect program—designed to non-invasively treat basal cell carcinoma (BCC). Cleveland Clinic Abu Dhabi is serving as the principal investigator, with additional recruitment planned across five major regional hospitals including Sheikh Shakbout Medical City and American Hospital Dubai. The study will enroll 36 participants across six UAE sites, coordinated by Insights Research Organization and Solutions (IROS), a member of the M42 healthcare portfolio. According to Dr. Raza Bokhari, Executive Chairman and CEO, this milestone "marks an important step in expanding Medicus's clinical footprint beyond the U.S.," underscoring the company's push to position SkinJect as a potential first-in-market non-invasive treatment for BCC—a global condition representing more than $2B in annual market potential. (MDCX) Bolsters Clinical Portfolio With Teverelix
—A Dual-Use Phase 2b Candidate Medicus Pharma (NASDAQ: MDCX) has completed its acquisition of Antev Limited, gaining control of Teverelix trifluoroacetate, a next-generation GnRH antagonist in late-stage development for both acute urinary retention (AURr) and high cardiovascular-risk prostate cancer. The move broadens (MDCX)'s clinical scope into two therapeutic areas with a combined $6B market potential.
Teverelix is designed for dual use: in AURr, a condition with high recurrence rates, it aims to become the first product to prevent relapse, supported by an FDA-cleared Phase 2b study of 390 patients. In prostate cancer patients with elevated cardiovascular risk, it is being evaluated in another FDA-cleared Phase 2b trial as a potentially safer alternative to conventional therapies. The acquisition also adds leadership depth, with veteran pharma executive Patrick J. Mahaffy joining the board. Together, the expanded pipeline and strengthened leadership put (MDCX) in position to reshape care across two areas of pressing medical need. Turning Point Ahead as Momentum Builds for (MDCX)
With late-stage programs advancing, growing clinical progress, and key regulatory steps approaching, (MDCX) is entering a pivotal phase. Momentum potential across its strategy and leadership has placed it firmly on our radar—and seven factors now stand out heading into this morning's session.
7 Reasons Why (MDCX) Is Topping Our Watchlist This Morning
—Friday, October 31, 2025
1. Small Float: with fewer than 5M shares available to the public, (MDCX)'s small float could see the potential for big moves if demand begins to shift. 2. Analyst Coverage: three firms—D. Boral Capital, Brookline Capital, and Maxim Group—have each reaffirmed bullish views on (MDCX), with targets reaching as high as $27, reflecting roughly 1,000% upside potential from recent levels. 3. Technical Strength: the chart for (MDCX) shows it trending near or above multiple key averages, including the 5-, 20-, 50-, and 100-day lines.
4. Recent Momentum: after an approximate 70% move in just three weeks last month, (MDCX) continues to attract focus from those tracking continuation patterns across the biotech sector. 5. Insider Confidence: leadership holds over half of (MDCX)'s shares, signaling strong alignment between internal vision and long-term goals. 6. Regulatory Progress: the FDA's recent Type C feedback supports (MDCX)'s plan to pursue the 505(b)(2) pathway for SkinJect, potentially shortening timelines for advancing its non-invasive BCC treatment. 7. Global Expansion: with its first patient treated in the UAE and additional sites now active, (MDCX)'s SkinJect program continues to demonstrate tangible progress on an international scale. All seven factors point to one conclusion—(MDCX) is entering a decisive stretch. With multiple potential catalysts aligning across its pipeline, this morning stands out as a moment to keep (MDCX) at the top of your radar. Take A Look At (MDCX) Before The Bell Rings…
With potential momentum building on multiple fronts, (MDCX) is standing out for all the right reasons. The company's low float of fewer than 5M shares, strong insider ownership above 50%, and technical strength across multiple moving averages together form a setup that's difficult to overlook. Layer in its expanding global Phase 2 work for SkinJect, the recently completed Antev acquisition, and fresh analyst targets reaching as high as $27—suggesting 1,000% upside potential from current levels—and it's easy to see why attention continues to grow around this name. We have all eyes on (MDCX) this morning. Take a look at (MDCX) before the bell rings. Also, keep a lookout for my next update, it could be hitting any moment. Sincerely,
Alex Ramsay
Co-Founder / Managing Editor Krypton Street Newsletter
| 
Tidak ada komentar:
Posting Komentar